本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●现金管理产品：技源集团股份有限公司（以下简称"公司"）拟使用部分暂 时闲置募集资金购买安全性高、流动性好、低风险、稳健型的保本型理财产品（单 项产品投资期限最长不超过12个月，包括但不限于结构性存款、协定存款、通知存 款、大额存单、收益凭证等）。该现金管理产品不得用于质押，不用于以证券投资 为目的的投资行为。 证券代码：603262 证券简称：技源集团 公告编号：2025-007 技源集团股份有限公司 ●现金管理额度及期限：公司拟使用总额不超过45,000万元（含本数）的闲置 募集资金进行现金管理，使用期限为自公司董事会审议通过之日起12个月内。在前 述额度和期限范围内，资金可循环滚动使用。 ●已履行的审议程序：公司召开第二届董事会第四次会议、第二届监事会第三 次会议，审议通过了《关于使用部分闲置募集资金进行现金管理的议案》，保荐机 构对公司本次使用部分闲置募集资金进行现金管理的事项无异议。本事项无需提交股 东大会审议。 ●特别风险提示：本次使用暂时闲置募集资金 ...

Group 1 - The company announced the use of idle raised funds for cash management, investing an amount of 55,000.00 million yuan in structured deposits [2] - The source of the funds is from the raised capital, and the investment is aimed at improving the efficiency of fund utilization [2] - The investment in principal-protected financial products is expected to enhance company earnings and maximize shareholder interests [2]

Core Viewpoint - The company has approved the use of temporarily idle raised funds for cash management, with a limit of up to RMB 900 million, to enhance the efficiency of fund utilization while ensuring the safety and liquidity of the investments [1][8][12]. Summary by Sections 1. Basic Situation of Raised Funds - The company raised a total of RMB 3,201,044,000 through its initial public offering, with a net amount of RMB 3,035,261,414.64 after deducting issuance costs [2][3]. - The funds have been deposited in a special account approved by the board of directors, and a tripartite supervision agreement has been signed with the sponsor and the bank [3]. 2. Investment Projects of Raised Funds - The raised funds are allocated for specific projects as outlined in the company's prospectus, with a total investment amount of RMB 246,813.72 million [5][6]. 3. Cash Management Arrangement - The company plans to use up to RMB 900 million of temporarily idle raised funds for cash management, with a maximum investment period of 12 months [8][9]. - The funds will be invested in low-risk, highly liquid financial products that meet capital preservation requirements, such as structured deposits and large certificates of deposit [8][9]. 4. Impact on the Company - The cash management initiative is designed to improve the efficiency of fund utilization without affecting the normal use of raised funds for investment projects [10][12]. - The company aims to generate additional returns for shareholders through prudent investment choices [10][12]. 5. Opinions from Supervisory Bodies - The supervisory board and the sponsor have reviewed and approved the cash management plan, confirming that it complies with relevant regulations and does not harm the interests of shareholders [12][13].

Core Viewpoint - The company, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., has announced the use of part of its idle raised funds for cash management, specifically investing in principal-protected financial products to enhance fund efficiency and shareholder returns [1][2][9]. Investment Overview - The investment amount for cash management is set at RMB 55 million [2]. - The funds are sourced from the net proceeds of a non-public offering approved by the China Securities Regulatory Commission, amounting to RMB 3,460,155,714.17, which was received on June 30, 2022 [2][3]. Investment Purpose - The purpose of this investment is to improve the efficiency and effectiveness of the raised funds while ensuring that it does not affect the construction of investment projects or the use of raised funds [2][9]. Investment Details - The company has approved the use of idle funds for principal-protected financial products with a maximum investment limit of RMB 1.5 billion, with individual product terms not exceeding 12 months [7][9]. - The financial products include structured deposits linked to the euro to US dollar exchange rate, with expected annualized returns ranging from 1.20% to 2.03% [6][8]. Risk Management - The financial products are categorized as principal-protected floating yield products, with overall risks being controllable. However, market fluctuations may still pose certain systemic risks [2][8]. - The company has established a risk control mechanism to monitor the investment and ensure the safety of funds [8]. Impact on the Company - The use of idle raised funds for cash management is designed to ensure that the progress of investment projects remains unaffected, thereby not significantly impacting the company's future business development, financial status, operating results, or cash flow [9]. - This strategy aims to enhance fund utilization efficiency and generate additional investment returns for shareholders [9].

格隆汇8月13日丨艾为电子(688798.SH)公布，为了提高公司募集资金使用效益，公司在确保不影响募集 资金投资项目建设、不变相改变募集资金使用用途、不影响公司正常运营及确保资金安全的情况下，同 意使用额度不超过人民币9亿元（含本数）的闲置募集资金进行现金管理，用于购买安全性高、流动性 好、满足保本要求的理财产品且该等现金管理产品不得用于质押，不用于以证券投资为目的的投资行 为，单个理财产品的投资期限不超过12个月。 ...

Core Viewpoint - The company, Aiwei Electronics (688798.SH), has announced a plan to utilize up to RMB 900 million of idle raised funds for cash management, ensuring that this does not affect the construction of investment projects or the normal operation of the company [1] Group 1 - The company aims to improve the efficiency of fund usage by investing in high-security, liquid financial products that meet capital preservation requirements [1] - The cash management products will not be used for pledging or for securities investment purposes [1] - The investment period for individual financial products will not exceed 12 months [1]

Core Viewpoint - Wuhan Keqian Biological Co., Ltd. plans to sign a cooperative research and development agreement with Huazhong Agricultural University, involving four vaccine projects, with a total payment of 4.9 million RMB [2][4][67]. Group 1: Overview of Related Transactions - The company has obtained cooperation for the development of four projects: "Canine Distemper, Canine Parainfluenza, Canine Adenovirus and Canine Parvovirus Quadrivalent Live Vaccine - Inactivated Canine Coronavirus Vaccine," "Porcine Gata Virus Inactivated Vaccine," "Porcine Proliferative Enteropathy Blocking ELISA Antibody Test Kit," and "NADC30-like Porcine Reproductive and Respiratory Syndrome Live Vaccine (GX2024 Strain)" [2][4][67]. - The total payment to Huazhong Agricultural University for these projects is 4.9 million RMB, with specific allocations of 1.5 million RMB, 2 million RMB, 400,000 RMB, and 1 million RMB for each project respectively [4][67]. - The transaction constitutes a related party transaction but does not qualify as a major asset restructuring under relevant regulations [2][4][67]. Group 2: Necessity and Impact of Related Transactions - The cooperative research aims to enhance the company's product portfolio and market competitiveness, although the success of the projects and their market introduction remain uncertain [67]. - The pricing and process of the transaction comply with legal regulations and do not harm the interests of the company or minority shareholders [67]. Group 3: Approval Procedures for Related Transactions - The board of directors and the supervisory board have approved the agreement, with related directors abstaining from voting [68][69]. - Independent directors have expressed that the agreement will enhance the company's core competitiveness in the biological products sector and that the transaction process is legal and fair [71][72]. Group 4: Research and Development Agreement Details - The agreement includes provisions for the rights and obligations of both parties, including the management of research funds and the ownership of intellectual property generated from the projects [8][37][52]. - The agreement is valid for 10 years, with provisions for extension and termination under certain conditions [20][36][66].

Core Viewpoint - The company plans to utilize idle raised funds for cash management, not exceeding RMB 260 million, to enhance fund efficiency while ensuring the normal operation of fundraising projects and maintaining fund safety [1][2][8] Summary by Sections Investment Purpose - The company aims to improve fund efficiency and increase shareholder returns by managing temporarily idle raised funds, ensuring it does not affect the progress of fundraising projects [5][7] Fund Source and Limit - The company will use up to RMB 260 million of idle raised funds for cash management, which can be rolled over within the specified limit [2][5] Investment Duration - The investment period is valid for 12 months from the date of the board's approval [5][6] Investment Method - The company will invest in high-security, liquid products such as structured deposits, time deposits, and large certificates of deposit, ensuring compliance with relevant regulations [5][6] Impact on Daily Operations - The cash management of idle funds will not affect the normal operation of fundraising projects and is expected to enhance overall performance and shareholder returns [7][8] Approval Process - The proposal for cash management has been approved by the board and supervisory board, complying with legal and regulatory requirements [8]

Summary of Key Points Core Viewpoint - The company intends to utilize idle raised funds for cash management to enhance fund efficiency and shareholder returns while ensuring that it does not affect the ongoing investment projects or the normal operations of the company [1][6]. Group 1: Fundraising and Usage - The company raised a total of RMB 1,227.45 million from its initial public offering (IPO) by issuing 105 million shares at a price of RMB 11.69 per share, with a net amount of RMB 1,141.73 million after deducting issuance costs of RMB 85.72 million [1][2]. - The total investment amount for the projects funded by the IPO is RMB 1,799.19 million, with RMB 1,747.03 million allocated from the raised funds [2]. - Due to a lower-than-expected net amount from the IPO, the company adjusted its investment projects, excluding certain projects and reallocating funds to ensure efficient use [2][3]. Group 2: Cash Management Plan - The company plans to use up to RMB 260 million of idle raised funds for cash management, ensuring that it does not impact the investment projects or the company's operations [3][5]. - The investment period for the cash management is valid for 12 months from the board's approval date, with a focus on low-risk, high-liquidity investment products [3][4]. - The income generated from cash management will be used to supplement any shortfall in the investment amounts for the projects and will be returned to the raised funds account upon maturity [4][6]. Group 3: Impact on Operations - The cash management of idle funds is expected to improve the efficiency of fund usage without affecting the normal progress of investment projects or the company's core business [4][6]. - By managing idle funds effectively, the company aims to achieve additional investment returns, thereby enhancing overall performance and providing greater returns to shareholders [4][6]. Group 4: Compliance and Approval - The cash management plan has been approved by the company's board and supervisory board, complying with relevant laws and regulations [5][6]. - The company will adhere to strict risk control measures and disclose information as required by regulatory authorities [4][6].

证券日报网讯 8月12日晚间，科前生物发布公告称，公司2025年8月12日召开第四届董事会第十三次会 议、第四届监事会第十二次会议审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意公司 使用额度不超过人民币26，000万元（含本数）的闲置募集资金在确保不影响募集资金投资项目进度、 不影响公司正常生产经营及确保资金安全的情况下进行现金管理，在上述额度范围内，资金可以滚动使 用，使用期限自公司董事会审议通过之日起12个月内有效。 （文章来源：证券日报） ...